Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Cuts 724 US Jobs To 'Reinvent' Pharma Business

Executive Summary

Boehringer Ingelheim is cutting 724 jobs in the US to "help us reinvent the way we serve the needs of our patients, and enable us to continue to make significant investments in research and development," which aligns with comments earlier this year by the German company's outgoing CEO.

You may also be interested in...



2Q Pharma Results Preview: What Lies Ahead

The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.

Green Shoots: Pharma Investments In Early Innovation Support Biotech Growth

Big pharma investments in early innovation are paying off in ways that still are hard to measure in any concrete way, but green shoots are sprouting through the pavement as startups supported by multimillion-dollar initiatives evolve from concept to reality.

Barner Goes Out On A High As Boehringer Ingelheim Returns To Growth

Professor Dr Andreas Barner, the outgoing chief of Boehringer Ingelheim, was able to report a return to growth for the family-owned German company in 2015 at his final annual conference. The group was boosted by diabetes sales under its partnership with Eli Lilly & Co - as well as by the strength of the dollar. The company reports in euros but books nearly 40% of its sales in the US. With currency effects stripped out, the sales were up by a more modest 4.1% versus the 11.1% as reported.

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel